Skip to main content
. 2016 Oct 27;8(20):33844–33854. doi: 10.18632/oncotarget.12953

Figure 2. Progression-free survival and overall survival according to FGFR2 amplification.

Figure 2

A. progression free survival was not significantly different between FGFR2 amplification group and no amplification group. B. FGFR2 amplification was associated with shorter overall survival.